Management Team & Advisors

Frances L. Johnson, MD


Frances L. Johnson, MD Acting Chief Executive Officer, Chief Medical Officer and Co-Founder of Viewpoint Molecular Targeting. Dr. Johnson is a physician scientist and entrepreneur with experience leading multi-disciplinary teams in academic, government and private enterprise settings. Dr. Johnson received a BS in Cell and Molecular Biology and a Doctorate in Medicine from the University of Washington followed by Internal Medicine residency at the University of California San Francisco and Cardiovascular Medicine fellowship at Stanford University. Her experience includes co-founding a biomedical startup (XDx; now CareDx, market capitalization $2.5B) as a co-inventor of their molecular diagnostic technology while on Stanford’s faculty. Dr. Johnson remained in academics during the growth phase of CareDx and led heart transplant teams at three academic medical centers before co-founding Viewpoint Molecular Targeting with Dr. Schultz and Mr. Coleman. As CEO/CMO at Viewpoint, Dr. Johnson has successfully secured multiple competitive Phase I and Phase II National Institutes of Health/National Cancer Institute funded Small Business Innovation Research Grants and Contract Projects ($10M). Dr. Johnson has successfully developed a team that has secured the first of two IND approvals expected in 2020 to begin the clinical trials of Viewpoint radiopharmaceuticals.


Michael K. Schultz, PhD


Michael K. Schultz, PhD is Chief Science Officer and Co-Founder of Viewpoint Molecular Targeting. He is the principal inventor of Viewpoint’s radiopharmaceuticals and directs ongoing development programs. Dr. Schultz is concurrently an Associate Professor of Radiology and Free Radical and Radiation Biology at the University of Iowa. Dr. Schultz has maintained continuous research funding for his laboratory for over a decade from the National Institutes of Health (NIH)/ National Cancer Institute (NCI) and has published over 75 peer-reviewed journal articles, book chapters, and invited publications. Dr. Schultz was awarded (as Co-Principal Investigator) a competitive NIH Research Project Grant (R01) to perform the non-clinical research and development needed to advance Viewpoint’s alpha-particle therapy for neuroendocrine tumors to a Phase 1 clinical imaging and therapy trial to be conducted at the University of Iowa. Dr. Schultz is Principal Investigator or Co-Investigator (with acting CEO and CMO Frances Johnson, MD of Viewpoint) on over $10M of NCI funded Small Business Innovation Research grant projects. In addition to his role on the current R01 ($3.5M), Dr. Schultz is a Project Leader for the University of Iowa NIH sponsored Specialized Project of Research Excellence in Neuroendocrine Tumors (a $10M, 5-year grant) and has been the primary architect, Principal Investigator, or Co-Investigator on over $20M in total of grants from the NIH, Nuclear Regulatory Commission, Department of Energy, Department of Homeland Security, and industry funded research projects. Dr. Schultz has 5 years of experience in product management in radiation detectors, electronics, and software (PerkinElmer/Ametec); 17 years of experience in radiopharmaceutical CMC/IND approvals; and served as a consultant to Algeta ASA (acquired by Bayer) on the CMC for the first alpha-particle targeted therapy approved in the United States (Xofigo).


Heyward H. Coleman, MBA


Heyward H. Coleman, MBA is Managing Director and Co-Founder of Viewpoint Molecular Targeting. Mr. Coleman is a serial entrepreneur who started his career in business with an MBA from Harvard School of Business after completing both service as an Officer in the United States Nuclear Navy, as well as receiving a Master’s Degree in Nuclear Physics from Duke University. Mr. Coleman’s previous achievements include founding, building, and eventually selling the largest privately held radioanalytical chemistry company in the United States (Environmental Physics; now General Engineering Laboratories). Mr. Coleman served as the inaugural CEO of Viewpoint and has assumed the role of Managing Director.

Board of Directors


Curtis Nelson, BBA


Curtis Nelson, BBA serves as the current Chairman of the Board at Viewpoint and is concurrently the President and CEO of the Economic Development Corporation. As a 1974 graduate from the University of Iowa, Mr. Nelson holds a BBA in Marketing and is also the author of The Recipe for Business Success. Mr. Nelson has over thirty-five years of successful national and international business creation and leadership experience – directing the development and successful launch of over 100 new businesses and more than 500 new products for the medical, health, communications, IT, military, transportation, food, and gardening industries worldwide. Mr. Nelson’s areas of expertise include starting-up and financing through a product development life cycle as well as management consulting in financials. Mr. Nelson is a successful entrepreneur, investor, seasoned public speaker,  consultant, and three-time veteran of Inc. Magazine’s 500 Fastest-Growing Private Companies® list (#48, #67, #225).


Frank Morich, MD PhD


Dr. Frank Morich is a biopharmaceutical professional with more than 35 years of industry experience. Since 2018 he serves on the board of CUE Biopharma in Boston, and became Chairman in 2020. From 2015 to 2020 he served on the board of Morphosys. Previously he served as a board member for Innate Pharma between 2004-2010, both clinical-stage biotechnology companies specializing in antibody development. Prior to focusing on board work, from 2011 to 2014, Dr. Morich served as Chief Commercial Officer at Takeda Pharmaceuticals, a global pharmaceutical company, and, from 2010 to 2011, he served as Executive Vice President, International Operations at Takeda. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical-stage drug development company, and, from 2005 to 2007, he served as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including member of the Board of Management of Bayer AG, Head of Global Product Development and Head of Research and Development. Dr. Morich holds an M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. He served as a military physician before moving to industry.

Charles Link.jpg

Charles Link, M.D., FACP


Dr. Link is a renowned oncologist and industry leader with over 21 years of experience. He was a practicing oncologist for 18 years, most recently at Medical Oncology and Hematology Associates of Iowa from 1995 to 2013. He also served as director of the Human Gene Therapy Research Institute, which is part of the John Stoddard Cancer Center at Iowa Methodist Medical Center.  Most recently, he served as the Co-founder and previous Chairman and Chief Executive Officer of NewLink Genetics, a pioneering immunotherapy company that discovered, developed and commercialized novel immuno-oncology product candidates, including checkpoint inhibitors and cellular immunotherapies. Over the course of his career, Dr. Link successfully completed multiple deals in excess of hundreds of millions of dollars with companies such as Novartis and Roche. Additionally, Dr. Link led the collaborative development of Merck’s EVERBO, the first Ebola vaccine to receive approval from the U.S. Food and Drug Administration. He has authored more than 170 scientific articles and abstracts and has received funding for his research from organizations such as the National Institutes of Health, National Cancer Institute, American Cancer Society, U.S. Army Breast Cancer Grant, and the Susan G. Komen Breast Cancer Foundation.

Advisory Board


Michael Graham, MD PhD


Michael Graham, MD PhD has been a leader in nuclear medicine and radiopharmaceuticals for over 30 years. Dr. Graham is a Professor of Radiology at the University of Iowa; a former President of the Society of Nuclear Medicine; and a current Co-Chair of the SNMMI Clinical Trials Network, which is an SNMMI entity that has been specifically formed to assist early stage companies in accelerating new radiopharmaceuticals through clinical stages of development. Dr. Graham has been a Principal Investigator on multiple IND filings and has recently provided leadership in securing an NDA for gallium-68 DOTATOC for imaging of neuroendocrine tumors through his efforts at the Clinical Trials Network. Dr. Graham earned a BS in Engineering from Massachusetts Institute of Technology; a PhD from University of California, Berkeley; and an MD from the University of California San Francisco. He served as Head of Nuclear Medicine at the University of Iowa for over a decade and is a world-renown content expert in image-guided radionuclide therapy for cancer and clinical trial design for this application.


Jeff Clanton, MS PharmD BCNP


Jeff Clanton MS PharmD BCNP, has been a leader in nuclear pharmacy and nuclear medicine for over 40 years and is a key opinion leader in this field. Dr. Clanton was a long-standing member of the Pharmacy and Therapeutics committee, Human Subjects Radiation Committee, Radiation Safety Committee, and Chairman of Radioactive Drug Research Committee. Dr. Clanton co-founded and co-owned an independent, commercial radiopharmacy and was responsible for operations and regulatory compliance. In addition, as a consultant for PETNET Pharmaceutical Services, he was responsible for the placement, build-out, training, compliance, and start-up of three PET cyclotron manufacturing facilities with pharmacies in Kentucky, Arkansas, and Louisiana. In recognition of his leadership, Dr. Clanton is the 2020 recipient of the William H. Briner Distinguished Achievement Award in Nuclear Pharmacy Practice. Dr. Clanton has provided leadership and oversight on numerous CMC/IND submissions as well as radiopharmacy operations and regulatory guidance for compliance (NRC, USP, cGMP and pharmacy law). During his 38+ year career at Vanderbilt University Medical Center, Dr. Clanton was Director of Radiopharmacy Services; Manager of the Cyclotron Facility; and a member of the Medical School Faculty, where he was responsible for production, operation, and delivery of prepared radiopharmaceuticals to patients. Dr. Clanton has authored or co-authored 90+ peer-reviewed scientific papers and 100+ abstracts for presentation at national meetings.


Nannette Rich, BS


Nannette Rich, BS is the president of NRich Consulting LLC and currently consults with clinical and preclinical stage radiopharmaceutical companies as well as investment institutions interested in this area. She has recently served as Vice President of Sales and Marketing at Telix Pharmaceuticals providing launch and marketing expertise. Ms. Rich has over 18 years of experience in marketing and sales, business development, portfolio management, and strategy in the radiopharmaceuticals and nuclear medicine industry for radioisotope imaging and therapeutics.  She has worked for companies including Cytyc (now Hologic), Mallinckrodt Pharmaceuticals (now Curium), Covidien, Burroughs Wellcome  (Glaxo SmithKline) and ETHEX Corporation. In her roles with these companies, Ms. Rich has provided leadership and guidance for founders and mature company management on product development, company process development, and regulatory strategy execution. Ms. Rich has consistently held roles in which she brought talent in the direction of marketing and sales for larger pharmaceutical companies as well as strategic commercialization informing clinical trial design for development-stage companies–leading companies from conception and formation through product launch and NDA and aNDA approvals.


Sue O’Dorisio, MD PhD


Sue O’Dorisio, MD, PhD is a Distinguished Professor of Pediatrics at the University of Iowa and a world-renowned leader in the adaptation of receptor-targeted image-guided radionuclide therapies for pediatric patient care. Dr. O’Dorisio earned a BS in Mathematics from Creighton University, an MS and PhD in Biochemistry from the University of Nebraska, and an MD cum laude from the Ohio State University, Columbus, OH. Dr. O’Dorisio is co-author of the  joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors and The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary thyroid cancer. Dr. O’Dorisio has served as Principal Investigator on numerous National Cancer Institute (NCI) supported clinical and preclinical investigations and is the Principal Investigator of the University of Iowa NCI funded ($10M) Specialized Program of Research Excellence in Neuroendocrine Tumors (NET SPORE). This program under Dr. O’Dorisio’s leadership is recognized as the only NET SPORE funded by the NCI in the United States and the University of Iowa is also a non-European based European Neuroendocrine Tumor Society Center of Excellence. Dr. O’Dorisio has been Principal Investigator on numerous investigator-initiated INDs for radionuclide therapy trials for pediatrics and brings a wealth of knowledge and understanding to the introduction of Viewpoint products for pediatric indications of neuroblastoma, medulloblastoma, paraganglioma, and pheochromocytoma.